Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Syros Pharmaceuticals, Inc. (SYRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/11/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/21/2023 8-K Quarterly results
07/17/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, dated May 2023",
"Data Demonstrate Encouraging Clinical Activity in Patients with PDAC Syros will present updated data from the single agent dose escalation portion and the gemcitabine/nab-paclitaxel combination safety lead-in portion of the Phase 1/1b trial. The maximum tolerated dose of SY-5609 as a single-agent was 10 mg using a 7 day on/7 day off dosing schedule. For the doublet, the MTD was 5 mg SY-5609 plus 1000 mg gemcitabine. A MTD was not established using the triplet cohort of SY-5609, gemcitabine and nab-paclitaxel. Each of the single-agent, doublet and the triplet regimens were generally well-tolerated with mostly low-grade events. Encouraging clinical activity was observed at the MTDs with SY-5609 both as a single-agent and in combination . Among the three response evaluable patients with selec..."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/01/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/21/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 9.9% stake in Syros Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc.
01/25/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 6% stake in Syros Pharmaceuticals, Inc.
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, dated January 2023",
"Syros Announces Clinical Updates and 2023 Strategic Priorities"
12/16/2022 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/14/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
10/06/2022 8-K Quarterly results
09/21/2022 D Form D - Notice of Exempt Offering of Securities:
09/20/2022 SC 13G Avidity Partners Management LP reports a 9.9% stake in Syros Pharmaceuticals, Inc.
09/19/2022 SC 13G Deep Track Capital, LP reports a 10% stake in SYROS PHARMACEUTICALS, INC.
09/19/2022 S-4MEF Form S-4MEF - Registration adding securities to prior Form S-4 registration [Rule 462(b)]:
09/16/2022 SC 13D/A TYME TECHNOLOGIES, INC. reports a 0% stake in Syros Pharmaceuticals, Inc.
09/16/2022 8-K Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modifications to Rights...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Certificate of Amendment to the Restated Certificate of Incorporation of the Company related to the Share Increase Amendment",
"Certificate of Amendment to the Restated Certificate of Incorporation of the Company related to the Stock Split Amendment",
"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement"
09/16/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/15/2022 425 Form 425 - Prospectuses and communications, business combinations:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy